IOncology

From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the contributors to the "Annual Advances in Clinical Oncology Research in China," Professor Biyun Wang from Fudan University Shanghai Cancer Center also detailed the ACE-Breast-02 study at this conference, showcasing the rigor and innovation of Chinese research. "Oncology Frontier" interviewed Professor Biyun Wang, and the compilation is presented below.

Dr. Hans Wildiers and colleagues published findings from the AIPAC Phase IIb trial (Clin Cancer Res, Feb 2024), evaluating eftilagimod alpha (efti), a soluble LAG-3 protein, in combination with paclitaxel…

With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People's Liberation Army General Hospital shared insights on the committee members' demeanor, the crucial role of young doctors within the association, and experiences and advice for young doctors on their growth path. Drawing from his own experiences, Professor Jiang encouraged young doctors to seize opportunities, actively engage in clinical practice and research, and contribute to both personal and societal value. He also offered words of encouragement to students aspiring to enter the medical field, urging them to pursue their dreams and contribute to the advancement of medical science in China.

The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a study analyzed the efficacy of different immunotherapy combinations for mCRPC patients and examined potential biomarkers.

In the second part of their discussion at ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) examined the evolving…

At ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) discussed VHL-associated renal cell carcinoma (RCC) and the latest Belzutifan data.…

European Hematology Association (EHA) 2024 Wrap-Up: A Confluence of Innovation and Collaboration The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology

Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year's study analyzed data from advanced UC patients in the United States. This article summarizes and organizes the findings for our readers.

From August 2-4, 2024, the Seventh Tumor Precision Diagnosis and Treatment Conference and the Tenth Breast Cancer Individualized Treatment Conference (COMB), hosted by the China Cancer Foundation and the Beijing Breast Disease Prevention and Treatment Society, were grandly held in Beijing. The conference brought together the latest advancements in individualized precision treatment of breast cancer in China, providing a broad stage for promoting new concepts, developing new technologies, and creating new models in the breast cancer field. "Oncology Frontier" specially interviewed the chairman of the COMB conference, Academician Binghe Xu from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, to highlight the key points of COMB, outline the blueprint for the development of innovative breast cancer drugs in China, and guide the research directions for immunotherapy in breast cancer.